LNAI Options (LNAI20260417P0.5) Price & Quote

Symbols

--(--)

Expected P&L on Expiry

Key Stats

0.00DAY`S RANGE0.00

Open

0.00

Prev.Close

0.00

Turnover

Volume

Premium

Extrinsic Value

Open Interest

Intrinsic Value

Pricing Model

Delta

Gamma

Theta

Vega

Rho

Theor Price

About LNAI20260417P0.5

Underlying

Lunai Bioworks Inc.

Industry

Biological Technology

Introduction

Lunai Bioworks Inc., incorporated in Delaware on January 18, 2011, operates through three subsidiaries: Renovaro Biosciences, Renovaro Cube and BioSymetrics. Renovaro Cube, including GediCube Intl. Ltd., and its subsidiaries, were acquired on February 13, 2024, and BioSymetrics and its subsidiaries were acquired on April 8, 2025. Renovaro Biosciences, the company's biotechnology division, focuses on the development of allogeneic cell and gene therapies designed to strengthen the immune response and designed to support long-term cancer remission. Following the acquisition of GediCube INTL., Lunai has increasingly emphasized molecular diagnostic and oncology technologies. The company's development areas include innovative therapeutic vaccination platforms for solid tumors such as pancreatic cancer, liver cancer, triple-negative breast cancer, and head and neck cancer. Its approach utilizes engineered donor cells and molecular diagnostic techniques that have the potential to provide "off-the-shelf" treatment options that reduce the delay between diagnosis and treatment.